Clinical study on the application of recombinant human brain natriuretic peptide in heart failure
重组人脑利钠肽在心力衰竭中的应用的临床研究

摘要

目的 该次试验将针对重组人脑利钠肽在心力衰竭疾病治疗中的应用效果展开分析探讨，期待能将所有研究理论应用至临床实际中，为领域发展形成促进。方法 研究对象均选自2024年8月至2025年8月间我院收治的心力衰竭患者中，共选取人数70例。采用简单随机分组法将其均分两组，每组归入35（n=35），分别命名为参照组与研究组，前者：施行常规治疗方案，后者：开展常规治疗的同时，增加重组人脑利钠肽治疗方案，而后进行疗效比对。结果 统计学分析后发现，研究组患者在整体疗效、心功能、血清学指标、血流动力学、安全性方面体现，均显优参照组（P＜0.05）。结论 对于心力衰竭患者而言，在其临床治疗方案的横向选择中，建议优先采用联合干预模式，即（常规治疗+重组人脑利钠肽）。这种模式一方面能够切实改善患者的心功能，减轻心肌损伤；另一方面，还能有效优化血流动力学参数。

Abstract

Objective This study aims to evaluate the therapeutic efficacy of recombinant human brain natriuretic peptide (rBNP) in heart failure management, with the goal of translating research findings into clinical practice and advancing the field.
Methods A total of 70 heart failure patients admitted to our hospital between August 2024 and August 2025 were randomly divided into two groups (n=35 each) using simple randomization. The control group received standard treatment protocols, while the study group received rBNP therapy alongside conventional treatments, with subsequent efficacy comparisons.
Results Statistical analysis demonstrated that the study group showed superior outcomes in overall clinical response, cardiac function, serum biomarkers, hemodynamic parameters, and safety compared to the control group (P <0.05).
Conclusion   For heart failure patients, a combined intervention approach combining standard therapy with rBNP appears superior. This dual-modality strategy not only effectively improves cardiac function and reduces myocardial damage but also optimizes hemodynamic parameters.